Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Retrophin takes on Questcor with ACTH analog, files for IPO

This article was originally published in Scrip

Executive Summary

Retrophin shares are trading for about twice as much as they did at the beginning of 2013 in the Over the Counter market, so it makes sense for the company focused on therapies for rare and serious diseases to pursue an initial public offering that will move its stock to the Nasdaq index and raise $40m to fund assets recently added to Retrophin's development pipeline.

Advertisement

Related Content

Mallinckrodt's FTC Settlement Seems A Blip For Acthar Blockbuster

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel